Enclomiphene Citrate Hair and Skin Changes: What the Clinical Evidence Shows

What Enclomiphene Citrate Is and How It Works

Enclomiphene citrate is the trans-isomer of clomiphene. Unlike racemic clomiphene, which contains roughly equal parts of the estrogenic zuclomiphene (cis) and anti-estrogenic enclomiphene (trans) isomers, the purified trans form acts almost exclusively as an estrogen-receptor antagonist at the hypothalamic-pituitary level. 1 Blocking hypothalamic estrogen receptors removes the negative feedback on GnRH, which increases pulsatile LH and FSH secretion, which in turn drives testicular testosterone synthesis.

The Androgenic Signal Driving Skin and Hair Changes

The testosterone rise produced by enclomiphene is substantial. In the proof-of-concept study by Kim et al. (BJU Int 2016, N=12), mean serum testosterone increased from hypogonadal baseline levels to the normal physiologic range while spermatogenesis was preserved. 1 A portion of that newly synthesized testosterone converts to dihydrotestosterone (DHT) via 5-alpha reductase in peripheral tissues, including the scalp, sebaceous glands, and dermis. DHT is the primary androgen responsible for androgenetic alopecia and sebaceous gland hypertrophy. 2

Why the Isomer Split Matters for Skin

Racemic clomiphene leaves zuclomiphene circulating for weeks after dosing stops because of its long half-life. Zuclomiphene has weak estrogenic agonist activity, which can partly offset androgen-driven sebum and collagen changes. Purified enclomiphene clears faster and carries almost no estrogenic agonism. 3 That pharmacokinetic difference means the skin environment under enclomiphene is governed more by the testosterone-estradiol ratio than by any residual SERM agonism.

Estradiol, produced by aromatization of the newly raised testosterone, does not disappear entirely. Aromatase activity in adipose tissue converts a fraction of the extra testosterone to estradiol, and estradiol has independent effects on skin collagen and sebum. 4

Hair Changes: Androgenetic Alopecia Risk

Enclomiphene does not directly cause hair loss. The mechanism is indirect: the drug raises testosterone, testosterone converts to DHT, and DHT binds androgen receptors in genetically susceptible hair follicles, shortening the anagen phase and miniaturizing the follicle over months to years. 5

Who Is at Highest Risk

Men carrying the AR gene variant on chromosome Xq11-12 are most vulnerable. A family history of male-pattern baldness on the maternal side is the strongest clinical predictor. 6 Men who had already noticed temporal or vertex thinning before starting enclomiphene are likely to see that process accelerate once testosterone, and therefore DHT, rises toward the normal range.

The degree of acceleration depends on:

• Baseline DHT-to-testosterone ratio (partly determined by 5-alpha reductase type II activity)
• Scalp androgen-receptor density
• Duration and dose of enclomiphene therapy
• Whether a 5-alpha reductase inhibitor (5-ARI) is co-prescribed

Clinical Evidence on Androgens and Follicle Miniaturization

No published randomized controlled trial has examined enclomiphene-specific alopecia as a primary endpoint. The mechanistic evidence comes from the broader testosterone-replacement and SERM literature. A 2019 review in the Journal of the American Academy of Dermatology confirmed that any intervention raising serum testosterone, including SERMs such as clomiphene citrate, carries a theoretical risk of accelerating androgenetic alopecia proportional to the DHT increment. 7 The American Academy of Dermatology 2023 guidelines on androgenetic alopecia name elevated androgens as a modifiable risk factor. 8

A Phase II placebo-controlled trial of enclomiphene (Androxal, Repros Therapeutics) in men with secondary hypogonadism and type 2 diabetes reported mean testosterone rising from 217 ng/dL to 419 ng/dL at 12 weeks on 25 mg/day. 9 DHT was not the primary outcome and was not systematically reported, but the magnitude of testosterone increase is consistent with a DHT rise of approximately 20 to 30 percent, based on conversion ratios established in TRT pharmacokinetics literature. 10

Practical Hair-Preservation Strategies

If a patient is genetically at risk for androgenetic alopecia, three evidence-based co-interventions exist:

1. Finasteride 1 mg/day (5-ARI): reduces scalp DHT by roughly 60 percent. 11 The trade-off is a modest reduction in the enclomiphene-mediated testosterone benefit and a small risk of sexual side effects.
2. Low-dose topical minoxidil 5% solution or 1 mg/day oral minoxidil: prolongs anagen phase independently of androgens. 12
3. Ketoconazole 2% shampoo: weak anti-androgenic effect at the follicle level, adjunctive use only. 13

Co-prescribing a 5-ARI with enclomiphene requires monitoring because finasteride lowers DHT but may slightly raise testosterone, creating a feedback that could modestly increase the testosterone dose-response. The prescribing clinician should recheck testosterone and DHT at 8 to 12 weeks after adding finasteride.

Skin Changes: Sebum, Acne, and Oiliness

Rising androgens increase sebaceous gland size and sebum output. This is one of the best-characterized androgen effects on skin physiology. 14 When enclomiphene raises testosterone from a hypogonadal baseline (below 300 ng/dL) toward the mid-normal range (400 to 700 ng/dL), sebum production tends to increase proportionally. 15

Acne Incidence in SERM and TRT Trials

No enclomiphene-specific acne incidence trial has been published. The closest proxy data come from:

• Racemic clomiphene trials in men: acne was not listed among the top adverse events in a 2012 systematic review of clomiphene for male hypogonadism, though increased oiliness was noted anecdotally. 16
• Testosterone-gel trials: the FDA-approved prescribing information for AndroGel 1.62% (testosterone) lists acne in 2 to 3 percent of subjects in registration trials. 17
• The Testosterone Trials (TTrials, N=790 men aged 65 and older): acne was reported in fewer than 5 percent of participants on testosterone gel, a rate slightly above placebo. 18

Because enclomiphene raises endogenous testosterone rather than delivering supraphysiologic exogenous hormone, the androgen load reaching the sebaceous gland is generally lower than in injectable TRT. Men who move from severe hypogonadism to normal testosterone will still experience a relative androgenic surge to their skin. 19

Which Skin Regions Are Most Affected

Sebaceous gland density is highest on the face (especially the T-zone), upper back, and chest. Those areas are, predictably, where androgen-driven acne and oiliness concentrate. A 2020 review in the British Journal of Dermatology described sebum secretion rate as rising approximately 2.5-fold when serum testosterone moves from castrate levels to the upper-normal male range. 20

Patients who had acne as teenagers, patients with polycystic-ovary-like sebaceous hyperactivity, and patients with naturally oily skin at baseline are most likely to notice increased oiliness within 4 to 8 weeks of starting enclomiphene. Comedone formation typically follows within 6 to 12 weeks if sebum is not managed. 21

Managing Enclomiphene-Associated Sebum and Acne

First-line options are topical: benzoyl peroxide 2.5 to 5% (reduces P. Acnes colonization), topical retinoids such as adapalene 0.1% gel (normalizes follicular keratinization), and non-comedogenic moisturizers to maintain barrier function. 22 For moderate to severe acne appearing after enclomiphene initiation, a dermatology referral is appropriate. Oral doxycycline 100 mg twice daily for 12 weeks is a standard second-line bridge while retinoid therapy takes effect. 23

Skin Quality: Collagen, Elasticity, and Wound Healing

Testosterone and estradiol both support dermal collagen synthesis. Hypogonadism is associated with reduced skin thickness, slower wound healing, and decreased type I collagen content. 24 Restoring testosterone to the physiologic range, whether through exogenous TRT or through enclomiphene-mediated endogenous production, may improve these parameters.

Collagen Synthesis and Androgen Receptors in Skin

Dermal fibroblasts express androgen receptors. Testosterone binding upregulates collagen type I and type III synthesis in vitro. 25 A 6-month open-label study of testosterone-gel therapy in hypogonadal men measured skin collagen by ultrasound and found a statistically significant increase in dermal thickness (P<0.05 vs. Baseline), with the greatest gains in men who had been most severely hypogonadal at entry. 26

Because enclomiphene achieves testosterone levels comparable to those in testosterone-gel trials, a similar collagen benefit is biologically plausible, though no enclomiphene-specific skin biopsy or imaging study has been published as of early 2025.

Estradiol's Role in Skin Hydration

Estradiol upregulates hyaluronic acid synthesis and aquaporin-3 expression in keratinocytes, both of which influence skin hydration. 27 Enclomiphene, by raising testosterone, also raises estradiol through aromatization. Men with higher adipose-tissue aromatase activity (typically those with higher BMI) will convert more testosterone to estradiol and may notice more pronounced skin hydration improvement. Men who are lean may see a smaller estradiol increment and a more predominantly androgenic skin phenotype: more sebum, less added hydration.

Wound Healing Observations

Animal-model data suggest that testosterone accelerates wound healing by increasing keratinocyte migration velocity and fibroblast proliferation. 28 Human data are limited but consistent with the animal findings: a small cross-sectional study (N=38) found that hypogonadal men had statistically longer wound closure times after standardized punch biopsies compared with eugonadal controls (P<0.05). 29 Whether enclomiphene-mediated testosterone restoration replicates this wound-healing benefit has not been directly tested.

Enclomiphene vs. Racemic Clomiphene: Differential Skin and Hair Profiles

The table below summarizes the key clinical differences between enclomiphene and racemic clomiphene as they relate to hair and skin outcomes. This framework was developed by the HealthRX medical team based on published pharmacokinetics, receptor-binding data, and clinical-trial adverse-event profiles.

| Parameter | Enclomiphene (trans) | Racemic Clomiphene | |---|---|---| | Estrogenic agonism at skin receptors | Minimal | Moderate (via zuclomiphene) | | Peak testosterone increment | 3 to 4x baseline (similar) | 2 to 3x baseline | | Sebum increase risk | Moderate (androgen-driven) | Moderate, partially offset by estrogen | | Androgenetic alopecia risk | Moderate to high in susceptible men | Moderate | | Skin hydration (via estradiol) | Proportional to aromatization rate | Higher (zuclomiphene adds estrogenic tone) | | Clearance from circulation | Rapid (days) | Slow (weeks for zuclomiphene) | | Acne incidence (proxy data) | Similar to TRT gel (~2 to 5%) | Similar; slightly higher in obese men |

The most clinically relevant difference: men on racemic clomiphene retain residual estrogenic agonism for weeks after each dose due to zuclomiphene accumulation. That persistent estrogen tone at skin receptors partially counteracts sebum increases. Enclomiphene does not produce that buffer. 3

Monitoring Protocol for Hair and Skin on Enclomiphene

A structured follow-up schedule reduces the chance of missing early androgenic skin changes. The following intervals reflect the Kim et al. Trial design and standard SERM monitoring practice. 1

Baseline Assessment

Before the first enclomiphene dose, document:

• Personal and family history of androgenetic alopecia (maternal uncle pattern is the highest-risk surrogate)
• Baseline Norwood-Hamilton scale for scalp hair
• Sebum output (oily vs. Normal vs. Dry skin self-report; Leeds scale if available)
• Serum testosterone (total and free), LH, FSH, estradiol, DHT, SHBG
• Fasting glucose and HbA1c if the patient also has type 2 diabetes (relevant to the Androxal trial population) 9

8-Week Follow-Up

Repeat testosterone, LH, FSH, estradiol, and DHT. Ask specifically about new scalp shedding (telogen effluvium triggered by the hormonal shift is possible in the first 8 to 12 weeks), facial oiliness, and new comedones. If DHT exceeds 100 ng/dL and the patient has Norwood grade 2 or higher, discuss adding finasteride or topical minoxidil. 11

12-Week and 6-Month Reviews

At 12 weeks, reassess the full hormone panel. The Androxal Phase II trial showed that testosterone gains were stable at 12 weeks without further titration at the 25 mg/day dose. 9 Photograph the vertex and frontal hairline at baseline and 6 months using standardized lighting (Canfield or equivalent) for objective comparison. Skin complaints that persist beyond 12 weeks despite topical management warrant dermatology co-management.

Special Populations and Considerations

Men With Pre-Existing Androgenetic Alopecia

Men already at Norwood grade 3 or higher should be counseled before starting enclomiphene that testosterone normalization is likely to accelerate existing follicle miniaturization, potentially by 6 to 18 months compared with the expected natural history. 30 Co-initiating finasteride 1 mg/day and enclomiphene simultaneously is a reasonable strategy backed by finasteride's registration trial data (Merck, N=1,553 over 2 years). 11

Men With Acne-Prone Skin or History of Cystic Acne

A personal history of severe nodulocystic acne requiring isotretinoin is a relative caution for any testosterone-raising therapy, including enclomiphene. The sebum increase that accompanies testosterone normalization can reactivate sebaceous hyperactivity. Patients in this category should establish care with a dermatologist before enclomiphene is started, rather than after acne flares. 31

Older Men and Skin Thinning

Men aged 60 and older tend to have lower 5-alpha reductase type II activity, which reduces DHT conversion from any given testosterone increment. 32 That biological fact makes severe androgenetic alopecia less likely in this group, and the collagen-synthesis benefits of testosterone normalization may be more apparent on net. The TTrials enrolled men with a mean age of 72, and dermatologic adverse events were not among the primary or key secondary endpoints. 18

Men on Concurrent 5-Alpha Reductase Inhibitors

Finasteride and dutasteride block DHT synthesis, which protects the scalp and sebaceous glands from androgen excess. However, 5-ARIs also reduce the testosterone-to-DHT conversion that contributes to libido and some aspects of erythropoiesis. Adding a 5-ARI to enclomiphene is pharmacologically logical for hair preservation, but the clinician should monitor hematocrit and sexual function at 3 months, given that both parameters can shift when the androgen environment changes. 33

What Patients Actually Report: Anecdotal Signals Worth Noting

No large observational registry has published patient-reported hair and skin outcomes specifically for enclomiphene. Anecdotal reports from men's health forums and clinical case series describe a pattern consistent with the mechanistic predictions: increased facial oiliness within 4 to 6 weeks, occasional new comedones on the back and shoulders, and in men with existing hair thinning, an increase in shed hairs during shampooing at 8 to 12 weeks. Skin hydration improvements and reduced dry-skin complaints are reported by some men, more often those who were severely hypogonadal at baseline (total T below 200 ng/dL). These self-reports align with the established androgen and estrogen physiology described above, but they should not substitute for controlled outcome data.

As the American Urological Association's 2018 guideline on testosterone deficiency states: "Clinicians should be aware that patient-reported outcomes may detect adverse effects not captured in formal trial protocols." 34

Regulatory Status and Off-Label Use Context

Enclomiphene citrate has not received FDA approval for secondary hypogonadism as of early 2025. Androxal (Repros Therapeutics) completed Phase III trials but was not approved, partly because the FDA requested an active comparator arm against testosterone gel. 35 It is prescribed off-label by men's health and endocrinology clinicians who prefer its preservation of the hypothalamic-pituitary-gonadal axis and spermatogenesis over exogenous TRT. 1 Because it is off-label, insurance coverage is inconsistent and compounded formulations from 503B pharmacies are common, which introduces variability in purity and dose. Patients should confirm that any compounded enclomiphene comes from an FDA-registered 503B outsourcing facility. 36